SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff (the Staff) of the Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance wi ...

Cidara Therapeutics, Inc. - Cidara Therapeutics, Inc.（NASDAQ:CDTX）是一家生物技术公司，利用其专有的Cloudbreak®平台开发药物-Fc结合物（DFC）免疫疗法，旨在拯救生命并改善面临严重疾病的患者的护理标准[1] - CD388的数据表明，在单次皮下注射给健康志愿者挑战流感后，DFC耐受性良好，并表现出统计学上显著的抗病毒效果[2] - CD388是一种正在研究的药物-Fc结合物（DFC），由多个副本的有效小分子神经氨酸酶抑制剂稳定地结合到人类抗体的专有Fc片段中组成[3]

Mundipharma合作协议 - 公司与Mundipharma签订资产购买协议，将rezafungin的商业权利转让给Mundipharma，预计可节省约1.28亿美元成本[1] - Mundipharma将承担ReSPECT Phase 3临床试验的进行和资金支持，以及rezafungin专利组合的成本和CMC和监管义务[2] - Mundipharma将获得所有未来来自Mundipharma和Melinta Therapeutics的未来版税和里程碑，以及rezafungin的知识产权、产品数据、监管批准等[3]

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline. "2023 included significant accom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-1537286 (State or Other Jurisdicti ...

逆向拆分公告 - Cidara Therapeutics, Inc.宣布进行股票逆向拆分，比例为1股拆分为20股[1] - 股东在2024年4月4日的特别股东大会上批准了逆向拆分提案，董事会于4月12日批准了1比20的逆向拆分[3] 交易时间 - 逆向拆分后的股票将于2024年4月24日开市后开始交易[2] 股票合并 - 逆向拆分导致每20股已发行和流通的普通股自动合并和转换为一股普通股[4]

Cidara Therapeutics公司在美国癌症研究协会年会上展示的海报 - 公司在2024年美国癌症研究协会年会上展示了四个海报，其中包括一份最新的海报展示[1] Cloudbreak平台在癌症预临床研究中的应用 - 公司的Cloudbreak平台快速产生了在各种癌症预临床研究中有效的DFC候选药物[2] Cidara Therapeutics公司的CBO421候选药物特点 - 公司的CBO421候选药物展示了强大的结合亲和力和对CD73的有效抑制[4]

REZZAYO批准 - 英国药品和医疗保健产品监管局（MHRA）批准了Cidara的REZZAYO（rezafungin acetate）用于治疗成人侵袭性念珠菌病[2] - REZZAYO的批准是基于ReSTORE第三期临床试验的积极结果，显示每周一次的rezafungin与标准治疗casposfungin相比具有统计学上的非劣性[3] Cidara与Mundipharma合作 - Cidara与Mundipharma合作，后者在美国和日本以外地区拥有rezafungin的商业权利，Cidara将从MHRA批准中获得约280万美元的里程碑付款[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1537286 (State or Other Juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1537286 (State or Other Jurisdicti ...